Menu

Calculators Drugs Pathways AI Dx Donate Get the App

Haematology Oncology Strong — Cairo-Bishop 2004 / Howard 2011

Tumor Lysis Syndrome Risk (Cairo-Bishop)

Cairo-Bishop criteria for laboratory and clinical Tumor Lysis Syndrome (TLS). Identifies patients needing prophylaxis or treatment.

Uric acid*

Potassium*

Phosphate*

Corrected calcium*

Clinical features of TLS*

Creatinine ≥ 1.5× ULN, cardiac arrhythmia, seizure, or death — in presence of laboratory TLS

Tumour type / burden (pre-treatment risk)*

High risk: Burkitt lymphoma, ALL, AML, bulky DLBCL, LDH > 2× ULN, WBC > 25×10⁹/L

References

Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004.
Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med. 2011.

Related

Curated clinical cross-links plus same-class fallbacks.

Drugs

Pathways

Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.